Innate Pharma (IPHA) Profit After Tax (2019 - 2022)
Innate Pharma (IPHA) has disclosed Profit After Tax for 1 consecutive years, with -$76.3 million as the latest value for Q4 2020.
- For the quarter ending Q4 2020, Profit After Tax changed N/A year-over-year to -$76.3 million, compared with a TTM value of -$76.3 million through Dec 2020, changed N/A, and an annual FY2024 reading of -$53.5 million, down 553.89% over the prior year.
- Profit After Tax was -$76.3 million for Q4 2020 at Innate Pharma.
- Across five years, Profit After Tax topped out at -$76.3 million in Q4 2020 and bottomed at -$76.3 million in Q4 2020.